Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters to the Editor

Staff  |  Issue: July 2007  |  July 1, 2007

In the old days, acute attacks were attenuated with ACTH and I have seen this work on several occasions. In your case, this might be like flogging a very tired horse. I doubt anyone could argue that a low, physiologic dose of systemic corticosteroid (prednisolone <8mg/d) produces immunosuppression and might be sufficient for the acute attack. If your patient had a brochospastic component, the pulmonary specialist would likely have recommended >2 mg/kg Q8hr with impunity. I would also give colchicine 0.6 mg BID for prophylaxis.

Matthew O. Swartz, MD, Rheumatologist

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Prince William Hospital, Manassas, Va.

 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I suggest either a moderated dose of systemic corticosteroids (i.e., prednisone 10 to 15 mg daily with a tapering regimen over two weeks) with continued close monitoring of fluid status or, if a clinician were feeling cavalier (vs. naive) enough or truly believed in his or her dexterity with a needle, an intra-articular corticosteroid injection to the affected gouty joint.

I recently had a similar situation and was able to maneuver a pleasant elderly woman out of it with the former tactic (though she had several affected gouty joints). Additionally, I have previously provided intra-articular corticosteroid injections to gouty joints in individuals who were anti-coagulated with thankful success. (Whether I possessed the correct thought process in attempting such a procedure under those conditions can be debated.) But I count my lucky stars that those individuals were able to avoid any complications from the procedure.

Lastly, I would also determine which option the treated individual prefers and/or is comfortable with and base my ultimate decision on their preference.

Dennis M. Liu, MD, Rheumatologist

Tuality Community Hospital, Hillsboro, Ore.

 

I have treated similar patients by injecting the joint with a 27-gauge, 1.5-inch needle. No problem with hemostasis.

Benjamin Lechner, MD, Rheumatologist

Hallandale, Fla.

 

Your patient was characteristic of 95% of those we now see, and meets “Lightfoot’s Criteria for Gout Needing a Rheumatologist”:

  1. Veteran;
  2. Heavy smoking history;
  3. Bruits in at least six sites, including at least one renal artery;
  4. Ejection fraction less than or equal to 25%;
  5. Creatinine around 2.5mg/dL on his or her best day;
  6. On coumadin for at least two of the following reasons:
    • Ventricular dilation with akinetic areas;
    • Recurrent thrombophlebitis;
    • Recurrent arterial thrombi from their plaques; and
    • An artificial heart valve.
  7. Enough exposure to alcohol to compromise easy regulation of prothrombin times; and
  8. Bronchopneumonia from tobacco-related lung disease.

In that setting, every drug for gout is contra-indicated. Therefore, the clinical decision-making is easy. You use the drug that is least worst.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:GoutQualityTreatment

Related Articles

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

    April 2, 2014

    Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered

    Case Report: Warfarin-Induced Non-Uremic Calciphylaxis Mimicking Vasculitis

    May 13, 2021

    Calciphylaxis, or calcific uremic arteriolopathy, is a rare disease characterized by calcification of the arterioles and capillaries in the dermis and subcutaneous tissue, resulting in thrombus formation and subsequent skin ischemia and necrosis.1 This serious condition most commonly occurs in patients with end-stage renal disease (ESRD) requiring dialysis or in kidney transplant recipients. In rare…

    Basics of Biologic Joint Reconstruction

    April 6, 2012

    For young patients especially, this can delay knee replacement and provide better outcomes.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences